FDA 483 - CellTrans, Inc. - May 06, 2021

An FDA inspection of CellTrans, Inc. in Chicago, IL, identified one observation related to clinical trial documentation. The firm, acting as a sponsor, failed to include the complete required ClinicalTrials.gov statement in informed consent documents for five subjects. This indicates a deficiency in adhering to regulatory requirements for clinical trial transparency and subject information.